Nizatidine ameliorates gastroparesis in Parkinson's disease: A pilot study. Issue 4 (27th December 2013)

• Record Type: Journal Article
• Authors: Doi, Hirokazu; Sakakibara, Ryuji; Sato, Mitsutoshi; Hirai, Shigekazu; Masaka, Tohru; Kishi, Masahiko; Tsuyusaki, Yohei; Tateno, Akihiko; Tateno, Fuyuki; Takahashi, Osamu; Ogata, Tsuyoshi
• Is Part Of: Movement disorders. Volume 29:Issue 4(2014)
• Page Start: 562
• Page End: 566
• Publication Date: 2013-12-27
• Subjects: Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.25777
• Languages: English
• ISSNs: 0885-3185

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <sec id="mds25777-sec-0001" sec-type="section"> <title>Background</title> <p>The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2‐receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a <sup>13</sup>C‐sodium acetate expiration breath test.</p> </sec> <sec id="mds25777-sec-0002" sec-type="section"> <title>Methods</title> <p>Twenty patients with PD were enrolled in the study. There were 13 men and 7 women; aged 68.0 ± 7.72 years; disease duration 5.50 ± 3.62 years. All patients underwent the breath test and a gastrointestinal questionnaire before and after 3 months of administration of NZT at 300 mg/day. Statistical analysis was performed by Student <italic>t</italic> test.</p> </sec> <sec id="mds25777-sec-0003" sec-type="section"> <title>Results</title> <p>NZT was well tolerated by all patients and none had abdominal pain or other adverse effects. NZT significantly shortened Tmax (<sup>13</sup>C) (the peak time of the <sup>13</sup>C‐dose‐excess curve) (<italic>P</italic> < 0.05).</p> </sec> <sec id="mds25777-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Although this is a pilot study, we found a significant shortening of gastric emptying time after administration of NZT in PD patients. © 2013 International Parkinson and Movement Disorder Society</p> </sec> </abstract>